The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves

Simply Wall St.07-06 04:19

Axsome Therapeutics, Inc. recently reported dosing the first patient in its FOCUS-3 Phase 3 trial of solriamfetol for adolescents with ADHD, while also being added to multiple Russell large-cap and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649619008?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-07-06 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649619008","market":"us","top_or_hot":-1,"title":"The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves","media":"Simply Wall St.","content":"<div>\n<p>Axsome Therapeutics, Inc. recently reported dosing the first patient in its FOCUS-3 Phase 3 trial of solriamfetol for adolescents with ADHD, while also being added to multiple Russell large-cap and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/the-bull-case-for-axsome-therapeutics-axsm-could-change-foll-2\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-06 04:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/the-bull-case-for-axsome-therapeutics-axsm-could-change-foll-2><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Axsome Therapeutics, Inc. recently reported dosing the first patient in its FOCUS-3 Phase 3 trial of solriamfetol for adolescents with ADHD, while also being added to multiple Russell large-cap and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/the-bull-case-for-axsome-therapeutics-axsm-could-change-foll-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/the-bull-case-for-axsome-therapeutics-axsm-could-change-foll-2","article_id":"2649619008","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/the-bull-case-for-axsome-therapeutics-axsm-could-change-foll-2","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649619008","pubTimestamp":1783282799,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Axsome Therapeutics, Inc. recently reported dosing the first patient in its FOCUS-3 Phase 3 trial of solriamfetol for adolescents with ADHD, while also being added to multiple Russell large-cap and growth indices and removed from several small-cap indices.\nThis combination of a pivotal late-stage CNS trial in a new age group and a shift into larger-cap equity benchmarks may influence how investors think about Axsome’s clinical profile and market positioning.\nWe’ll now examine how the Phase 3...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","ADHD":"Alcobra Ltd.","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","BK4505":"高瓴资本持仓","ABVC":"ABVC BioPharma, Inc.","BK4139":"生物科技","AXSM":"Axsome Therapeutics, Inc.","BK4007":"制药"},"translate_title":"Axsome Therapeutics(AXSM)的牛市可能会在3期ADHD试验和指数变动后发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTH":0.6,"AXSM":1.5,"ADHD":1.5,"ABVC":1.5},"content_text":"Axsome Therapeutics, Inc. recently reported dosing the first patient in its FOCUS-3 Phase 3 trial of solriamfetol for adolescents with ADHD, while also being added to multiple Russell large-cap and growth indices and removed from several small-cap indices. This combination of a pivotal late-stage CNS trial in a new age group and a shift into larger-cap equity benchmarks may influence how investors think about Axsome’s clinical profile and market positioning. We’ll now examine how the Phase 3 FOCUS-3 trial initiation for adolescent ADHD reshapes Axsome Therapeutics’ broader investment narrative. Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.AdvertisementAxsome Therapeutics Investment Narrative RecapTo own Axsome, you need to believe in its ability to turn a focused CNS portfolio into a sustainable, profitable business while managing heavy R&D and commercial spend. The FOCUS-3 ADHD trial and Russell index shifts support the idea of a broader, more visible platform, but they do not change the key near term swing factors: execution on Auvelity, Sunosi and Symbravo, and the risk that elevated costs and pricing pressure keep net losses higher for longer. The most relevant recent announcement here is the first patient dosing in FOCUS-3, which extends solriamfetol into adolescent ADHD on top of its ongoing Phase 3 in MDD with excessive daytime sleepiness. Together, these late stage programs sit alongside Auvelity’s new Alzheimer’s agitation indication and Symbravo’s migraine launch as important potential contributors to future revenue, but also as drivers of higher R&D and SG&A that investors need to weigh carefully against Axsome’s current unprofitable status. Yet behind the appeal of new CNS indications, investors should be aware that rising gross to net discounts and ongoing net losses could... Read the full narrative on Axsome Therapeutics (it's free!)Axsome Therapeutics' narrative projects $2.5 billion revenue and $981.8 million earnings by 2029.Uncover how Axsome Therapeutics' forecasts yield a $276.47 fair value, a 13% upside to its current price.Exploring Other PerspectivesAXSM 1-Year Stock Price Chart Some analysts were far more cautious, assuming Axsome must grow revenue to about US$1.5 billion and earnings to roughly US$433.1 million by 2029, which sets a higher bar for the ADHD program and broader late stage pipeline to shift their more pessimistic view.Explore 7 other fair value estimates on Axsome Therapeutics - why the stock might be worth less than half the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Axsome Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.No Opportunity In Axsome Therapeutics?Opportunities like this don't last. These are today's most promising picks. Check them out now:Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649619008","isCrawlerRequest":true}